Vaxcyte (PCVX) Stock Forecast, Price Target & Predictions
PCVX Stock Forecast
Vaxcyte stock forecast is as follows: an average price target of $124.14 (represents a 16.57% upside from PCVX’s last price of $106.49) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
PCVX Price Target
PCVX Analyst Ratings
Vaxcyte Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 10, 2024 | Salim Syed | Mizuho Securities | $163.00 | $115.28 | 41.39% | 53.07% |
Sep 04, 2024 | Jason Gerberry | Bank of America Securities | $140.00 | $110.15 | 27.10% | 31.47% |
Sep 03, 2024 | David Risinger | Leerink Partners | $153.00 | $112.04 | 36.56% | 43.68% |
Sep 03, 2024 | Tom Shrader | BTIG | $160.00 | $110.15 | 45.26% | 50.25% |
Sep 03, 2024 | Roger Song | Jefferies | $129.00 | $111.13 | 16.09% | 21.14% |
Sep 03, 2024 | Salim Syed | Mizuho Securities | $113.00 | $111.08 | 1.72% | 6.11% |
Aug 07, 2024 | Tom Shrader | BTIG | $98.00 | $70.52 | 38.97% | -7.97% |
Jan 03, 2023 | - | Needham | $58.00 | $47.95 | 20.96% | -45.53% |
Dec 16, 2022 | - | Leerink Partners | $60.00 | $45.48 | 31.93% | -43.66% |
Dec 15, 2022 | - | Guggenheim | $66.00 | $45.72 | 44.36% | -38.02% |
Vaxcyte Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 7 | 7 |
Avg Price Target | - | $136.57 | $136.57 |
Last Closing Price | $106.49 | $106.49 | $106.49 |
Upside/Downside | -100.00% | 28.25% | 28.25% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 04, 2024 | Guggenheim | Buy | Buy | Hold |
Sep 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
Sep 03, 2024 | Needham | Buy | Buy | Hold |
Sep 03, 2024 | BTIG | Buy | Buy | Hold |
Sep 03, 2024 | Jefferies | Buy | Buy | Hold |
Aug 07, 2024 | BTIG | Buy | Buy | Hold |
Mar 12, 2024 | Morgan Stanley | Buy | Buy | Hold |
Mar 12, 2024 | Wedbush | Buy | Buy | Hold |
Jan 03, 2023 | Needham | Buy | Buy | Hold |
Dec 16, 2022 | SVB Leerink | - | Outperform | Initialise |
Vaxcyte Financial Forecast
Vaxcyte Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | $166.67K |
High Forecast | - | - | - | - | - | - | - | $166.67K |
Low Forecast | - | - | - | - | - | - | - | $166.67K |
# Analysts | - | - | - | - | - | - | - | 1 |
Surprise % | - | - | - | - | - | - | - | - |
Vaxcyte EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 |
EBITDA | - | - | - | - | - | - | - | $-19.96M |
Avg Forecast | - | - | - | - | - | - | - | $-12.81M |
High Forecast | - | - | - | - | - | - | - | $-10.24M |
Low Forecast | - | - | - | - | - | - | - | $-15.37M |
Surprise % | - | - | - | - | - | - | - | 1.56% |
Vaxcyte Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 |
Net Income | - | - | - | - | - | - | - | $-20.32M |
Avg Forecast | $-164.16M | $-158.30M | $-158.30M | $-152.43M | $-136.89M | $-129.08M | $-114.39M | $-13.12M |
High Forecast | $-164.16M | $-158.30M | $-158.30M | $-152.43M | $-136.89M | $-115.91M | $-114.39M | $-10.50M |
Low Forecast | $-164.16M | $-158.30M | $-158.30M | $-152.43M | $-136.89M | $-143.57M | $-114.39M | $-15.74M |
Surprise % | - | - | - | - | - | - | - | 1.55% |
Vaxcyte SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 |
SG&A | - | - | - | - | - | - | - | $2.01M |
Avg Forecast | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - |
Vaxcyte EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 20 | |
---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 |
EPS | - | - | - | - | - | - | - | $-1.72 |
Avg Forecast | $-1.40 | $-1.35 | $-1.35 | $-1.30 | $-1.17 | $-1.10 | $-0.98 | $-1.27 |
High Forecast | $-1.40 | $-1.35 | $-1.35 | $-1.30 | $-1.17 | $-0.99 | $-0.98 | $-1.27 |
Low Forecast | $-1.40 | $-1.35 | $-1.35 | $-1.30 | $-1.17 | $-1.22 | $-0.98 | $-1.27 |
Surprise % | - | - | - | - | - | - | - | 1.36% |
Vaxcyte Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
VTYX | Ventyx Biosciences | $2.15 | $33.86 | 1474.88% | Buy |
STRO | Sutro Biopharma | $3.69 | $11.14 | 201.90% | Buy |
LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
IMCR | Immunocore | $31.17 | $70.75 | 126.98% | Buy |
SNDX | Syndax Pharmaceuticals | $18.94 | $36.11 | 90.65% | Buy |
LEGN | Legend Biotech | $43.61 | $82.62 | 89.45% | Buy |
VRDN | Viridian Therapeutics | $22.84 | $37.83 | 65.63% | Buy |
LQDA | Liquidia | $10.46 | $17.17 | 64.15% | Buy |
BMRN | BioMarin Pharmaceutical | $66.01 | $101.70 | 54.07% | Buy |
MRUS | Merus | $51.23 | $77.13 | 50.56% | Buy |
AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
TECH | Bio-Techne | $75.90 | $91.69 | 20.80% | Buy |
NUVL | Nuvalent | $89.53 | $107.83 | 20.44% | Buy |
TVTX | Travere Therapeutics | $18.10 | $21.38 | 18.12% | Buy |
PCVX | Vaxcyte | $106.49 | $124.14 | 16.57% | Buy |
ACLX | Arcellx | $86.44 | $71.57 | -17.20% | Buy |
PCVX Forecast FAQ
Is Vaxcyte a good buy?
Yes, according to 8 Wall Street analysts, Vaxcyte (PCVX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 100.00% of PCVX's total ratings.
What is PCVX's price target?
Vaxcyte (PCVX) average price target is $124.14 with a range of $58 to $163, implying a 16.57% from its last price of $106.49. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vaxcyte stock go up soon?
According to Wall Street analysts' prediction for PCVX stock, the company can go up by 16.57% (from the last price of $106.49 to the average price target of $124.14), up by 53.07% based on the highest stock price target, and down by -45.53% based on the lowest stock price target.
Can Vaxcyte stock reach $200?
PCVX's average twelve months analyst stock price target of $124.14 does not support the claim that Vaxcyte can reach $200 in the near future.
What are Vaxcyte's analysts' financial forecasts?
Vaxcyte's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-380M (high $-367M, low $-395M), average SG&A $0 (high $0, low $0), and average EPS is $-3.244 (high $-3.131, low $-3.367). PCVX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-633M (high $-633M, low $-633M), average SG&A $0 (high $0, low $0), and average EPS is $-5.4 (high $-5.4, low $-5.4).